Imarech (Imatinib mesylate) Blood Cancer medicine

Name of Medicine: Imarech

Composition: Imatinib Mesylate 400mg

Chemical Formula: C30H35N7O4S

Description: Imarech is a formulation of Imatinib Mesylate, available as tablets in the strength of 400mg for oral use.

What is Imarech?
Imarech is a prescription drug that belongs to a class of medications known as anti-cancer agents. It is an effective formulation of a kinase inhibitor namely Imatinib Mesylate. Imarech (Imatinib Mesylate) tablet inhibits the proliferation and induces apoptosis (planned cell death) in BCR-ABL positive cells (cancer cells).

Clinical Relevance
Imarech, comprising Imatinib Mesylate, is a kinase inhibitor prescribed for the treatment of:

Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP); provided- after the failure of interferon-alpha therapy.

Ph+ CML in chronic phase (newly diagnosed or recurred).

Relapsed Philadelphia chromosome-positive agents acute lymphoblastic leukemia (Ph+ ALL).

Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements.

Aggressive systemic mastocytosis (ASM).

Hypereosinophilic syndrome (HES).

Chronic eosinophilic leukemia (CEL).

Metastatic dermatofibrosarcoma protuberans (DFSP)

Positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).